Clark David Michael's Form 4 filing
Amicus Therapeutics, Inc. (FOLD) · filed Jan 6, 2023
- Accession no.
- 0001209191-23-002393
- Filed
- Jan 6, 2023
- Trade date
- Jan 4-6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $255.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Clark David MichaelCIK 0001755662 | Officer (Chief People Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2023 | Common Stock | FTax withholdingDisposed | −2,692 | $12.03 | −$32,384.76 | 241,073 | Direct | |
| Jan 6, 2023 | Common Stock | SSaleDisposed | −21,507 | $11.87F2 | −$255,288.09 | 219,566 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.75 to $11.98. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.